Subacute Delirium: Comprehensive Research Report

Note on Nosology

"Subacute Delirium" is not an independently defined disease entity with its own genetic or pathophysiological literature — it is a temporal-course descriptor within the single clinical syndrome of delirium. ICD-10-CM code F05 ("Delirium due to known physiological condition") is explicitly defined to include "acute or subacute confusional state," "acute or subacute brain syndrome," and "acute or subacute psycho-organic syndrome," with F05.1 covering delirium superimposed on dementia icd10data.com. MONDO (MONDO:0004629) and UMLS/MedGen (C0154333, SNOMED CT 191507002) carry "Subacute Delirium" as a synonym set ("Delirium, Subacute"; "Subacute confusional state") mapped onto the same underlying concept as delirium generally MedGen C0154333. Consequently, this report treats "subacute delirium" as delirium with a subacute onset/course (onset over days rather than hours, and/or a protracted duration of weeks rather than days) and draws on the delirium literature broadly, flagging the subset of studies that specifically address protracted/persistent/subacute courses (Sections 8 and 11 in particular).

1. Disease Information

Overview. Delirium is an acute neuropsychiatric syndrome of disturbed attention, awareness, and cognition that develops over a short period (hours to days — "acute") or, in the subacute variant, over a somewhat longer interval, and represents a direct physiological consequence of an underlying medical condition, substance intoxication/withdrawal, or medication effect, or multiple combined etiologies [MalaCards / MONDO:0004629 description via search]. Core features include a disturbance of attention and awareness, an additional cognitive disturbance (memory, disorientation, language, visuospatial ability, or perception), development over a short period with a tendency to fluctuate in severity during the day, and evidence that the disturbance is not better explained by a pre-existing/evolving dementia.

Key identifiers: | Ontology | Identifier | |---|---| | MONDO | MONDO:0004629 ("subacute delirium") | | UMLS/MedGen | C0154333 | | SNOMED CT | 191507002 | | ICD-10-CM | F05 (Delirium due to known physiological condition — "acute or subacute confusional state"); F05.1 (superimposed on dementia) | | DSM-5 | Delirium, specified as acute (hours–days) or persistent (weeks–months) |

Synonyms: Subacute confusional state; acute confusional state; toxic-metabolic encephalopathy; organic brain syndrome (historical term); ICU psychosis (informal, ICU-specific); sundowning (informal, when evening-predominant) MedGen C0154333.

Data source note: Most quantitative data below derive from aggregated, cohort-level clinical research (hospital registries, ICU cohorts, meta-analyses) rather than individual EHR mining per se, though several cited studies (e.g., UK Biobank-linked COVID-19 cohort, US World Delirium Awareness Day prevalence study) are EHR/registry-based.

2. Etiology

Causal framework. Delirium arises from an interaction between predisposing (vulnerability) factors and precipitating (insult) factors — a patient with high vulnerability (e.g., advanced age, dementia) can develop delirium from a minor insult, while a resilient patient requires a major insult (multiple simultaneous new medications, major surgery, severe critical illness).

Direct causal factors: - Systemic infection/sepsis and acute critical illness - Major surgery/anesthesia (postoperative delirium) - Metabolic derangement (electrolyte disturbance, hypo-/hyperglycemia, hepatic/renal failure) - Medication effects, polypharmacy, and substance intoxication/withdrawal (including alcohol and benzodiazepine withdrawal) - Hypoxia/hypoperfusion - Primary CNS insults (stroke, seizure, traumatic brain injury, CNS infection)

Genetic risk factors. The largest multi-ancestry GWAS of delirium to date analyzed 1,059,130 individuals (11,931 cases) and identified APOE as a strong risk locus, with the effect persisting after adjustment for dementia/Alzheimer's disease and within dementia-free cohorts — indicating APOE independently confers delirium vulnerability rather than acting solely through dementia risk PLOS Medicine GWAS. A large UK cohort further found that APOE ε4 genotypes increased risk of delirium during COVID-19-related hospitalizations PMC8344705. Additional postoperative-delirium-associated loci include APOC1, TOMM40, and PVRL2, genes previously linked to dementia, cognitive decline, and cerebral imaging phenotypes [Neuroscience News summary]. Notably, earlier candidate-gene associations between the muscarinic cholinergic receptor genes CHRM2 and CHRM4 and postoperative delirium were not replicated in more recent, better-powered analyses, with all three previously identified variants showing null effects medRxiv / Nature Aging, Dissecting the genetic and proteomic risk factors for delirium.

Environmental/clinical risk factors (odds ratios from recent meta-analyses of hospitalized older patients): - Frailty: OR ≈ 2.05 - Physical restraints: OR ≈ 5.01 - Prior falls: OR ≈ 1.99 - Severe illness: OR ≈ 1.32 - Cognitive impairment/dementia: OR ≈ 2.61 ScienceDirect, Global incidence and prevalence of delirium, 2024; PubMed 39602991

Other established risk factors include advanced age, polypharmacy (especially anticholinergics, benzodiazepines, opioids), sensory impairment (vision/hearing), immobility, dehydration, sleep deprivation, indwelling catheters/lines, and mechanical ventilation.

Protective factors. Multicomponent nonpharmacological prevention programs are the best-evidenced protective intervention (see Section 13); no robust genetic protective variant has been established, though the absence of the APOE ε4 allele is associated with lower risk by extension of the GWAS findings above.

Gene-environment interaction. The APOE-delirium association is modulated by acute physiological stressors (e.g., COVID-19 infection, surgery), consistent with a "two-hit" model in which genetic vulnerability (APOE-mediated neuronal/glial resilience) interacts with an environmental/physiological precipitant (infection, surgery, critical illness) to produce clinical delirium PMC8344705.

3. Phenotypes

Delirium's phenotype spans cognitive, behavioral, and psychomotor domains, with laboratory/imaging correlates increasingly recognized as biomarker-level abnormalities.

Motor subtypes and frequency. A subacute-care cohort study of patients ≥65 admitted with delirium found: hyperactive delirium 40.6%, mixed 31%, hypoactive 25.9%, nonmotor 2.6% [PubMed search — persistent delirium subtype study]. Hypoactive delirium, though less prevalent in some settings, is disproportionately missed clinically because of its quiet presentation.

Onset/severity/progression per DSM-5: Delirium severity is formally specified as acute (a few hours to days) or persistent (weeks to months) — the "subacute" category sits at the acute-to-persistent transition, typically representing onset over roughly 1–2 weeks with a course of several weeks [DSM-5 criteria search summary].

Frequency/persistence data: Combined proportions of patients with persistent delirium were 44.7% at discharge, 32.8% at 1 month, 25.6% at 3 months, and 21% at 6 months in an updated systematic review and meta-analysis medRxiv persistent delirium meta-analysis; Delirium Journal version. In patients with and without dementia, delirium symptoms persisted up to 12 months post-diagnosis, with inattention, disorientation, and impaired memory the most persistent individual symptoms in both groups.

Quality of life impact: Persistent/subacute delirium is associated with functional decline, increased nursing-home placement, and worse cognitive trajectory relative to patients whose delirium resolves acutely PMC5506578, subsyndromal delirium meta-analysis.

4. Genetic/Molecular Information

Delirium is not a monogenic disorder; there is no single causal gene analogous to a Mendelian disease. Rather, common-variant susceptibility loci modulate risk in the context of an acute precipitant.

• APOE (chr19; HGNC:613) — strongest and most replicated genetic risk factor identified in the largest delirium GWAS to date (N=1,059,130, 11,931 cases), independent of dementia status PLOS Medicine.
• APOC1, TOMM40, PVRL2 (NECTIN2) — chromosome 19 loci in linkage disequilibrium with APOE, associated with postoperative delirium and broader neurocognitive phenotypes.
• CHRM2, CHRM4 (muscarinic acetylcholine receptors) — earlier candidate-gene hits, not replicated in recent, adequately powered analyses (null effect in the 2024/2025 genetic-proteomic dissection study) Nature Aging 2025.

Proteomic/functional correlates: The same 2024–2025 genetic-and-proteomic dissection identified multiple blood-based proteins predictive of delirium risk years in advance, including markers of brain injury and inflammation not previously linked to delirium — supporting a model in which chronic subclinical neuronal vulnerability (proteomically detectable) interacts with an acute precipitant Nature Aging; PMC12823428.

Functional consequence framing: These findings support a susceptibility/modifier model (GENO: GENO:0000217 susceptibility) rather than a loss/gain-of-function causal mutation model — APOE ε4 carriage confers relative risk via impaired neuronal lipid transport, reduced synaptic resilience, and amplified neuroinflammatory response to systemic insults, rather than through a specific structural variant.

Epigenetics/chromosomal abnormalities: No delirium-specific epigenetic signature or chromosomal abnormality has been established in the literature surveyed; delirium is fundamentally a syndromic, precipitant-driven state superimposed on variable genetic vulnerability rather than a primary genetic or chromosomal disorder.

5. Environmental Information

Environmental/iatrogenic factors: - Polypharmacy — anticholinergics, benzodiazepines, opioids, corticosteroids - Physical restraints (independently associated risk, OR ≈ 5.01) [ScienceDirect 2024 meta-analysis] - Indwelling catheters, intravenous lines, mechanical ventilation - ICU environment: sleep deprivation, sensory overload/deprivation, lack of day-night cues - Surgery/anesthesia exposure (postoperative delirium)

Lifestyle/patient-level factors: Pre-existing frailty, immobility, dehydration, malnutrition, sensory impairment (uncorrected vision/hearing loss), and sleep disruption are all established contributors, consolidated in the "predisposing × precipitating factor" model of delirium.

Infectious triggers: Systemic infection/sepsis is one of the most common precipitants; COVID-19 specifically has been shown to precipitate delirium at elevated rates in APOE ε4 carriers PMC8344705. LPS (bacterial endotoxin)-driven systemic inflammation is the standard experimental proxy for infection-triggered delirium in animal models (see Section 15).

6. Mechanism / Pathophysiology

Delirium's mechanism is multifactorial and converges on acute, reversible cortical-subcortical network dysfunction driven by systemic and neuro-inflammation, neurotransmitter imbalance, and blood-brain barrier compromise.

Causal chain (systemic trigger → clinical syndrome): 1. Systemic insult (infection, surgery, metabolic derangement) → release of peripheral pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) and cortisol. 2. Blood-brain barrier (BBB) dysfunction — increasingly recognized as a key permissive mechanism allowing peripheral inflammatory signals to reach the CNS PMC11622424, Pathophysiology and Biomarkers of Delirium. 3. Neuroinflammation — microglial activation, NF-κB pathway activation, and local cytokine release (TNF-α, IL-1β, PGE2, nitric oxide) in the hippocampus and cortex, demonstrated mechanistically in LPS mouse models Scientific Reports LPS study. 4. Neurotransmitter dysregulation — dysregulated cholinergic (relative deficiency) and dopaminergic (relative excess) signaling is a long-standing mechanistic hypothesis, though the specific cholinergic receptor gene candidates have not held up genetically (see Section 4). 5. Synaptic and network dysfunction — disrupted thalamocortical and frontal-parietal connectivity. 6. Clinical manifestation — inattention, disorientation, and fluctuating consciousness.

Molecular pathways: NF-κB signaling (pro-inflammatory transcription); cortisol/HPA-axis signaling exacerbating neuroinflammation and impairing synaptic function Frontiers postoperative delirium biomarkers review.

Cellular processes: Microglial activation and synaptic remodeling/pruning; astrocytic activation (reflected by S100B elevation); neuronal injury (reflected by NfL, tau, pTau elevation) PMC11622424; PMC10985356, Serum NFL and tau.

Network/circuit-level findings (neuroimaging): - Reduced functional connectivity of the intralaminar thalamic and caudate nuclei with other subcortical regions during a delirium episode, which recovers after resolution AJP, Neural Network Functional Connectivity During and After an Episode of Delirium. - Disrupted reciprocal (inverse) coupling between the dorsolateral prefrontal cortex and posterior cingulate cortex — normally anti-correlated, these regions become abnormally positively correlated during delirium. - EEG shows increased delta/theta power, reduced alpha power, and reduced functional connectivity, and loss of feedback cortical connectivity has been specifically implicated Alzheimer's & Dementia 2024, Gjini et al.; Frontiers EEG systematic review.

Biochemical/biomarker abnormalities: Elevated IL-6, CRP, TNF-α (systemic inflammation, variable specificity); S100B and NfL show the most consistent CNS-injury-marker associations with delirium presence and severity, implicating astrocytic and axonal injury respectively PMC12401822, Serum biomarkers of delirium in critical illness systematic review. A 2024/2025 CSF study found CSF sIL-6R correlated with plasma IL-6/IL-8 and with blood-brain barrier permeability (CSF:plasma albumin ratio, plasma S100B), directly linking peripheral inflammation to BBB compromise in postoperative delirium BJA Open.

GO/CL/UBERON term suggestions: - GO:0034612 (response to tumor necrosis factor), GO:0032496 (response to lipopolysaccharide), GO:0007249 (I-kappaB kinase/NF-kappaB signaling), GO:0006954 (inflammatory response) - CL:0000129 (microglial cell), CL:0000127 (astrocyte) - UBERON:0001954 (Ammon's horn/hippocampus), UBERON:0002435 (striatum, incl. caudate), UBERON:0002444 (thalamus), UBERON:0009834 (dorsolateral prefrontal cortex)

7. Anatomical Structures Affected

Organ level: Primary organ affected is the brain (central nervous system); delirium is by definition a whole-brain functional (not typically focal-structural) disturbance, though it frequently co-occurs with the organ system driving the underlying precipitant (e.g., respiratory failure, sepsis-affected multiple organs, post-surgical state).

Tissue/regional level: - Thalamus (intralaminar nuclei) — reduced functional connectivity during delirium - Basal ganglia / caudate nucleus — reduced subcortical connectivity - Prefrontal cortex (dorsolateral) — disrupted reciprocal connectivity with posterior cingulate - Posterior cingulate cortex — abnormal positive coupling with DLPFC during delirium - Hippocampus — site of microglial activation and neuronal injury in animal models (LPS)

Subcellular level (GO Cellular Component): Synapse (GO:0045202), microglial process, astrocytic end-foot at the blood-brain barrier (relevant to BBB dysfunction mechanism).

Localization: Diffuse/bilateral cortical-subcortical network disturbance rather than a single lateralized lesion; this distinguishes delirium from focal stroke-related confusional states.

8. Temporal Development

Onset: - Acute delirium: onset over hours to a few days (DSM-5). - Subacute delirium: onset over an intermediate timeframe, typically several days to roughly 1–2 weeks, representing an insidious rather than abrupt presentation — often seen with slowly evolving metabolic derangements, indolent infections, or medication accumulation effects, and clinically important because it is more easily mistaken for evolving dementia MedGen C0154333 clinical research summary. - Delirium can occur at any adult age but disproportionately affects older adults; onset in critical illness or postoperative settings is typically within the first several days of the inciting event.

Progression / course pattern: - Fluctuating course is a defining diagnostic feature — symptom severity waxes and wanes over the course of a day, classically worsening in the evening ("sundowning"). - DSM-5 persistence specifier: acute (hours–days) vs. persistent (weeks–months) — subacute delirium occupies the transition zone and often evolves into persistent delirium if the underlying precipitant is not resolved. - Persistent delirium prevalence: 44.7% at hospital discharge, declining to 32.8% (1 month), 25.6% (3 months), and 21% (6 months) in a pooled meta-analysis of older hospitalized patients medRxiv. - Symptoms can persist up to 12 months, with inattention, disorientation, and memory impairment the most persistent individual features [search summary, persistent delirium 12-month follow-up].

Remission patterns: Delirium is classically defined as reversible with treatment of the underlying cause, though full cognitive recovery is not universal — a substantial minority never return to baseline cognition, particularly in patients with pre-existing cognitive impairment.

Critical periods / intervention windows: The subacute-to-persistent transition represents a key intervention window — early identification and treatment of the underlying precipitant during the subacute phase is associated with better functional and cognitive outcomes than intervention after the delirium becomes persistent PMC12404460, Persistent inpatient delirium and increased LOS/mortality.

9. Inheritance and Population

Epidemiology: - Pooled prevalence 23.6% and pooled incidence 13.5% among medically hospitalized older patients (recent systematic review/meta-analysis) ScienceDirect 2024; PubMed 39602991. - US hospitalized-patient prevalence ranges ~16–18%, rising to ~23.6% in older adults specifically. - 2023 US cross-sectional World Delirium Awareness Day study: clinically documented delirium prevalence 16.4% (morning) and 17.9% (evening) assessments ScienceDirect. - Prevalence reaches up to 50% in hospitalized elderly populations broadly, and ~32.5% incidence among critically ill (ICU) patients, rising further with mechanical ventilation and organ dysfunction; ~47.7% prevalence among post-surgical ICU patients [search summary]. - Community-dwelling older adults: systematic review of prevalence/incidence/risk factors in home settings (BJGP 2025) BJGP.org.

Inheritance pattern: Not a Mendelian disorder — complex/multifactorial, with common-variant (APOE) susceptibility contributing modest, non-deterministic risk in the context of an acute precipitant. No formal penetrance, expressivity, anticipation, mosaicism, or founder-effect data are applicable in the Mendelian sense; APOE ε4 allele frequency itself varies by ancestry (well-characterized in gnomAD/population genetics resources independent of delirium).

Population demographics: - Age: strongest independent risk factor — prevalence rises sharply with advancing age, particularly ≥65 years. - Sex: no strong, consistent sex-ratio skew reported across the reviewed epidemiological studies; risk is driven primarily by frailty, comorbidity burden, and acute illness severity rather than sex per se. - Setting-specific demographics: nephrology ward cohorts, pneumonia cohorts (5-decade prevalence/mortality meta-analysis), and emergency-department ambulance-arrival cohorts each show elevated delirium prevalence in older, frailer sub-populations PMC12565244; PMC12148281; PMC11950662.

10. Diagnostics

Clinical/bedside diagnostic tools: - Confusion Assessment Method (CAM) — the most widely used bedside screening/diagnostic algorithm, requiring acute onset/fluctuating course + inattention, plus either disorganized thinking or altered consciousness [search summary, DSM-5/CAM comparison]. - CAM-ICU — ICU-adapted version for non-verbal/ventilated patients. - DSM-5 criteria — considered relatively more restrictive than DRS-R98 or CAM in head-to-head comparisons, identifying a somewhat different (often narrower) case set PMC4207319, DSM-IV vs DSM-5 concordance; PubMed 25601222; PubMed 28903799. - DRS-R98 (Delirium Rating Scale-Revised-98) — severity-graded instrument, used as a comparator/gold standard in validation studies. - Level-of-arousal-inclusive DSM-5 interpretation is argued to be "safer" (more sensitive) for capturing genuine delirium cases PMC4177077.

Laboratory tests: No delirium-specific diagnostic lab test exists; work-up targets the underlying precipitant — CBC, metabolic panel, liver/renal function, TSH, blood/urine cultures, ammonia, toxicology screen as clinically indicated.

Emerging biomarkers (research/investigational, not yet routine clinical diagnostics): - S100B and neurofilament light chain (NfL) — most consistent CNS-injury-marker associations with delirium presence/severity across a systematic review of serum biomarkers in critical illness PMC12401822. - Serum tau and NfL correlated with delirium in a 3-year retrospective analysis, while serum UCHL-1, GFAP, and CSF SNAP-25/NPTX2/sTREM2 did not PMC10985356. - CSF IL-6, soluble IL-6 receptor, and IL-6 trans-signalling complex associated with postoperative delirium in an observational cohort BJA Open. - EEG-based quantitative/functional-connectivity measures — increased delta/theta power, reduced alpha power, reduced connectivity, and loss of feedback cortical connectivity are being explored as objective, non-invasive diagnostic adjuncts Frontiers systematic review; Alzheimer's & Dementia 2024. - Bispectral EEG has also been used as a discovery platform to identify novel protective agents for infection-related delirium in preclinical models Translational Psychiatry 2024.

Genetic testing: Not clinically indicated for delirium diagnosis (it is an acute syndromic diagnosis, not a genetic disease); APOE genotyping is a research risk-stratification tool, not a diagnostic test.

Differential diagnosis: Dementia (chronic, typically non-fluctuating, preserved consciousness), depression (particularly in hypoactive delirium), primary psychiatric psychosis, non-convulsive status epilepticus, stroke/focal neurological deficit, and delirium superimposed on dementia (ICD-10 F05.1) — which is common and requires careful distinction of an acute change from the patient's cognitive baseline.

Screening: No population-level genetic or newborn screening applies (delirium is an acquired, precipitant-driven acute-care condition); "screening" in practice means routine CAM/CAM-ICU or 4AT bedside screening of at-risk hospitalized patients (elderly, ICU, postoperative) rather than genetic carrier screening.

11. Outcome/Prognosis

Mortality: - Persistent delirium is associated with increased 30-day mortality and higher 60-, 90-, 180-, and 360-day mortality, with an incremental increase in mortality risk for each additional day of delirium [search summary, persistent delirium outcomes meta-analysis]; PMC12404460, increased LOS and mortality. - Outcomes (mortality, nursing-home placement, function, cognition) for patients with persistent delirium are consistently worse than for patients who recover from delirium PMC5506578; PubMed 19017678, systematic review of frequency and prognosis.

Long-term cognitive outcomes / dementia risk: - A meta-analysis of 23 studies found delirium significantly associated with long-term cognitive decline (Hedges g = 0.45, 95% CI 0.34–0.57, P<.001) JAMA Neurology meta-analysis; PubMed 32658246. - Patients experiencing in-hospital delirium showed markedly increased dementia risk post-discharge (OR ≈ 5.37, P<.001) compared with those without delirium [search summary]. - A separate estimation study modeled how many dementia cases might be prevented by preventing delirium, underscoring delirium as a modifiable dementia risk factor rather than a purely bystander phenomenon PubMed 37031027. - A recent (2025) systematic review/meta-analysis of long-term clinical outcomes after hospital discharge for delirium further consolidates the adverse-outcome signal Age and Ageing 2025.

Morbidity/function: Increased length of stay, functional decline, and nursing-home placement are consistently reported; hyperactive, mixed, hypoactive, and nonmotor delirium subtypes differ in discharge destination and functional trajectory in subacute-care cohorts.

Prognostic factors: Duration of delirium (each additional day worsens mortality risk), pre-existing dementia, frailty, and severity of the underlying precipitating illness are the most consistently reported prognostic modifiers.

12. Treatment

Pharmacotherapy: - Antipsychotics (haloperidol, ziprasidone): The NEJM MIND-USA trial found no significant difference between haloperidol, ziprasidone, and placebo for delirium duration or severity in critically ill patients NEJM 2018, Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness(landmark trial; foundational to current guideline skepticism about routine antipsychotic use). A 2024 follow-up analysis of long-term outcomes similarly found no difference in long-term quality of life with haloperidol vs. placebo across the identified trials ScienceDirect 2024, MIND-USA long-term outcomes. - Dexmedetomidine (alpha-2 agonist): The 4D trial (2024/2025) compared haloperidol-first-then-dexmedetomidine strategies for hyperactive delirium in non-intubated ICU patients, finding improved agitation control, reduced need for additional medications, and reduced ICU length of stay/costs with the dexmedetomidine-inclusive strategy Intensive Care Medicine 2025; PMC12678554. - Olanzapine vs. low-dose dexmedetomidine: A 2024 randomized trial in critically ill patients directly compared these agents AJRCCM 2024. - Dexmedetomidine + melatonin for post-CABG delirium: a 2023 RCT (n=80) found delirium occurrence lower with combined dexmedetomidine+melatonin (15%) vs. dexmedetomidine alone (30%) PMC10664157.

Suggested NCIT terms: NCIT:C15986 (Pharmacotherapy) for the generic action, with therapeutic_agent bindings to CHEBI for haloperidol, ziprasidone, olanzapine, dexmedetomidine, and melatonin individually.

Non-pharmacological / supportive care: Reorientation, early mobilization, sleep-hygiene protocols, hearing/vision aid provision, hydration/nutrition support, and minimizing deliriogenic medications and physical restraints — the core components of the Hospital Elder Life Program (HELP) (see Section 13), applied both preventively and as first-line management of established delirium.

Rehabilitation: Physical and occupational therapy to address functional decline associated with persistent delirium; NCIT:C15302 (Physical Therapy).

Experimental/investigational: Bispectral-EEG-guided discovery platforms are being used to screen for novel protective agents against infection-related delirium in preclinical models Translational Psychiatry 2024.

Treatment strategy summary: Current evidence favors treating the underlying precipitant first, applying non-pharmacological multicomponent strategies as first line, and reserving antipsychotics/dexmedetomidine for severe agitation or patient/staff safety concerns rather than as disease-modifying therapy — reflecting the accumulated null results for antipsychotics on delirium duration/long-term outcomes.

13. Prevention

Primary prevention — multicomponent nonpharmacological interventions: - The Hospital Elder Life Program (HELP), developed by Sharon K. Inouye's group at Yale (1999), bundles reorientation, early mobilization, therapeutic activities, hydration/nutrition support, sleep-protocol strategies, and hearing/vision adaptation PMC3724594. - The original NEJM 1999 trial established multicomponent targeted intervention efficacy for preventing delirium onset and reducing total delirium-days in hospitalized older medical patients NEJM 1999. - A 2024 systematic review/meta-analysis of HELP found subgroup effect estimates of RR ≈ 0.65 (HELP programs) and RR ≈ 0.70 (non-HELP multicomponent programs) for delirium incidence reduction ScienceDirect 2024. - A 2024/2025 umbrella review of RCTs for delirium prevention/treatment interventions further consolidates this evidence base ScienceDirect umbrella review. - Nurse-led multicomponent interventions have separately been shown effective in a 2025 systematic review/meta-analysis Journal of Advanced Nursing 2025.

Secondary prevention: Routine bedside screening (CAM/CAM-ICU/4AT) of at-risk hospitalized, postoperative, and ICU patients for early detection, permitting prompt treatment of an emerging precipitant before delirium becomes persistent/subacute-to-chronic.

Tertiary prevention: Once delirium is established, minimizing deliriogenic medications, restraints, and immobility, and aggressively treating the underlying condition, reduces progression to persistent delirium and its associated mortality/cognitive-decline risk.

Pharmacological prophylaxis: Evidence for pharmacological delirium prophylaxis (e.g., prophylactic antipsychotics or dexmedetomidine) remains mixed and is not a first-line recommendation given the null long-term outcome data for antipsychotics; nonpharmacological multicomponent prevention remains the standard of care.

Counseling: Not applicable in the genetic-counseling sense (delirium is not a heritable single-gene disorder); patient/family education regarding delirium risk, expected fluctuating course, and reorientation strategies is a core component of both prevention and management.

14. Other Species / Natural Disease

Delirium as classically defined is a human clinical/DSM construct; there is no widely characterized spontaneous veterinary "delirium" literature comparable to human clinical case series. However: - Veterinary anesthesia/critical-care literature describes post-anesthetic emergence delirium/dysphoria and ICU-associated confusional states in companion animals (dogs, cats) that are mechanistically analogous (systemic inflammation, anesthesia, critical illness precipitating acute confusional states), though this is not formally captured in OMIA as a discrete inherited disease. - The orthologous APOE gene is broadly conserved across mammals (NCBI Gene), consistent with cross-species use of Apoe-knockout or humanized-APOE mouse lines in delirium-adjacent neuroinflammation research (see below).

15. Model Organisms

Primary model: LPS (lipopolysaccharide)-induced systemic inflammation in mice. This is the dominant experimental proxy for infection-triggered delirium: - LPS administration produces acute-onset, fluctuating cognitive impairment meeting DSM-IV-analogous criteria in mice, with microglial activation and neuronal cell loss in the hippocampus, assessed via Morris water maze and passive avoidance tests Scientific Reports 2019; PMC6453933. - LPS increases TNF-α, IL-1β, PGE2, and nitric oxide, with NF-κB pathway activation, directly modeling the neuroinflammatory mechanism described in Section 6. - Interventional studies in this model include deferoxamine (iron chelation) attenuating LPS-induced neuroinflammation/memory impairment PMC4323121, a Banhasasim-Tang (traditional herbal formulation) attenuation study PMC7400939, and hippocampal GPR17 knockdown/inhibition attenuating LPS-induced cognitive impairment PMC10662506.

Perioperative/subclinical infection combination model: A novel adult mouse model combining subclinical infection with surgery to induce cognitive dysfunction has been developed specifically as a model for perioperative neurocognitive disorder, closer to the clinical postoperative-delirium scenario than LPS alone PMC12832885.

Baseline vulnerability models: Mouse models with pre-existing cognitive impairment/neurodegenerative pathology (e.g., amyloid-pathology models) show progressively increased "delirium-like" susceptibility to a superimposed acute inflammatory insult, mechanistically supporting the predisposing-factor × precipitating-factor clinical model PMC4278840, Worsening Cognitive Impairment and Neurodegenerative Pathology Progressively Increase Risk for Delirium.

Model limitations: Mouse "sickness behavior" (reduced activity, reduced food intake) following LPS overlaps with but is not identical to human delirium's core attention/awareness disturbance, which is difficult to operationalize behaviorally in rodents; most LPS studies rely on validated cognitive-impairment proxies (water maze, passive avoidance) rather than a direct delirium-equivalent readout, so translational fidelity for the attentional component of delirium specifically remains an open limitation.

Applications: These models are used to dissect the neuroinflammation → BBB dysfunction → microglial activation → cognitive impairment causal chain, to screen candidate protective/therapeutic agents (e.g., the bispectral-EEG-guided discovery platform noted in Section 12) Translational Psychiatry 2024, and to test genetic-risk-modifying manipulations (e.g., Apoe-genotype mouse lines, though a delirium-specific Apoe-mouse study was not identified in this search and would be a natural translational follow-on to the human GWAS findings in Section 4).

Summary for Knowledge-Base Curation

"Subacute Delirium" should be curated as a temporal/course variant within the single delirium pathophysiology module rather than as a structurally distinct disease mechanism — the causal chain (systemic insult → BBB dysfunction → neuroinflammation → thalamocortical/frontal network dysfunction → clinical syndrome) is shared across acute, subacute, and persistent presentations, with course duration and reversibility as the key differentiating Descriptor (temporality: SUBACUTE / CHRONIC, clinical_course: PROGRESSIVE for cases evolving toward persistent delirium or dementia). APOE (hgnc:613) is the best-supported genetic modifier and should be entered as a SUSCEPTIBILITY relationship type rather than a causal gene. S100B and NfL are the most defensible biomarker phenotypes for a Biochemical/laboratory-abnormality entry given consistency across recent systematic reviews.

Sources

• Subacute delirium (MedGen C0154333) — NCBI
• subacute delirium — Monarch Initiative MONDO:0004629
• The Pathophysiology and Biomarkers of Delirium — PMC
• Serum biomarkers of delirium in critical illness: systematic review — PMC
• Emerging biomarkers of postoperative delirium — Frontiers
• Serum NFL and tau correlate with delirium — PMC10985356
• CSF IL-6/sIL-6R and postoperative delirium — BJA Open
• Persistent delirium in older hospital patients: updated systematic review — medRxiv
• Persistent delirium in older hospital patients — Delirium Journal
• Persistent delirium: frequency and prognosis — PubMed 19017678
• Persistent inpatient delirium, length of stay, mortality — PMC12404460
• Outcomes of subsyndromal delirium in ICU — PMC5506578
• Global incidence and prevalence of delirium — ScienceDirect 2024
• Global incidence/prevalence of delirium — PubMed 39602991
• Delirium among older adults living at home — BJGP 2025
• Delirium in the US: 2023 World Delirium Awareness Day study — ScienceDirect
• Prevalence/risk factors of delirium in nephrology ward — PMC12565244
• Five-decade prevalence of delirium in pneumonia — PMC12148281
• Delirium at ED arrival by ambulance — PMC11950662
• DSM-IV vs DSM-5 delirium concordance — PMC4207319
• Comparison of delirium diagnosis: CAM, DRS-R98, DSM-IV, DSM-5 — PubMed 25601222
• Outcomes by diagnostic system for delirium — PubMed 28903799
• DSM-5 criteria, arousal, and delirium diagnosis — PMC4177077
• Genetic architecture of postoperative delirium — PLOS Medicine
• Dissecting the genetic and proteomic risk factors for delirium — Nature Aging
• Dissecting the genetic and proteomic risk factors for delirium — PMC12823428
• Gene Discovery Reveals Hidden Risk Pathway for Delirium — Neuroscience News
• APOE ε4 genotypes and delirium risk during COVID-19 — PMC8344705
• Association of Delirium With Long-term Cognitive Decline: Meta-analysis — JAMA Neurology
• Association of Delirium With Long-term Cognitive Decline — PubMed 32658246
• Preventing dementia by preventing delirium — PubMed 37031027
• Long-term clinical outcomes of delirium after discharge — Age and Ageing 2025
• Neural network functional connectivity during/after delirium — AJP
• EEG functional connectivity for delirium detection — Frontiers 2023
• Delirium and loss of feedback cortical connectivity — Alzheimer's & Dementia 2024
• ICD-10-CM F05 codes — icd10data.com
• Haloperidol and Ziprasidone for Delirium in Critical Illness — NEJM
• Long-term outcomes after antipsychotic treatment of delirium (MIND-USA) — ScienceDirect 2024
• 4D Trial: Dexmedetomidine for hyperactive delirium — Intensive Care Medicine 2025
• 4D Trial — PMC12678554
• Olanzapine vs low-dose dexmedetomidine — AJRCCM 2024
• Dexmedetomidine + melatonin for post-CABG delirium — PMC10664157
• Hospital Elder Life Program design/methods — PMC3724594
• Original HELP trial — NEJM 1999
• HELP systematic review/meta-analysis — ScienceDirect 2024
• Umbrella review of delirium prevention/treatment RCTs — ScienceDirect
• Nurse-led multicomponent interventions — Journal of Advanced Nursing 2025
• Neuroinflammation induced by LPS causes cognitive impairment in mice — Scientific Reports
• LPS-induced cognitive impairment — PMC6453933
• Deferoxamine attenuates LPS-induced neuroinflammation — PMC4323121
• Banhasasim-Tang attenuates LPS-induced cognitive impairment — PMC7400939
• Hippocampal GPR17 knockdown attenuates LPS-induced cognitive impairment — PMC10662506
• Subclinical infection + surgery mouse model — PMC12832885
• Cognitive impairment/neurodegeneration and delirium risk — PMC4278840
• Bispectral EEG discovery of protective agents for infection-related delirium — Translational Psychiatry 2024

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

• DOI:10.1056/NEJMoa1808217)(landmark (1 mention) - Identifier did not resolve to a record